Clinical efficacy of combined treatment methods in uncontrolled arterial hypertension during pregnancy
Received: 2025-12-12 11:51:19
Published: 2026-03-29
Abstract
Aim: To evaluate the effect of combined antihypertensive therapy on arterial blood pressure parameters in pregnant women with uncontrolled gestational arterial hypertension.
Materials and methods: The study included 60 pregnant women diagnosed with gestational arterial hypertension according to the 2018 ESC recommendations, with a gestational age of 20–24 weeks. The patients were randomly divided into two groups: Group 1 (n = 30) — methyldopa (500–1000 mg) + metoprolol succinate (25–50 mg), Group 2 (n = 30) — methyldopa (500–1000 mg) + amlodipine (5–10 mg). In all patients, office arterial blood pressure was measured and 24-hour ambulatory blood pressure monitoring was performed before the initiation of antihypertensive therapy.
Results: A significant decrease in systolic, diastolic, and mean arterial blood pressure was recorded in both groups (p < 0.0001). The degree of blood pressure reduction was higher in Group 2 in terms of systolic and diastolic parameters, which may be explained by the vasodilatory effect of amlodipine. Target systolic blood pressure was observed in 75% of patients in Group 1 and 87% of patients in Group 2, while target diastolic blood pressure was observed in 75% and 91% of patients, respectively. However, no statistically significant difference was found between the groups.
Conclusion: Both combined antihypertensive therapy regimens ensured the achievement of target arterial blood pressure levels in pregnant women with gestational arterial hypertension. Although the methyldopa and amlodipine combination showed a greater tendency toward blood pressure reduction, larger studies are required to confirm these results.
Keywords
List of references
-
Khan, K. S., Wojdyla, D., Say, L., Gülmezoglu, A. M., and Van Look, P. F. (2006). WHO analysis of causes of maternal death: a systematic review. Lancet 367 (9516), 1066–1074. https://doi.org/10.1016/S0140-6736(06)68397-9.
-
Hitti, J., Sienas, L., Walker, S., Benedetti, T. J., and Easterling, T. (2018). Contribution of hypertension to severe maternal morbidity. Am. J. Obstet. Gynecol. 219 (4), e1–e405. https://doi.org/10.1016/j.ajog.2018.07.002
-
Magee LA, von Dadelszen P, Rey E, et al. Control of hypertension in pregnancy (CHIPS) trial. BMJ. 2015;350:h349. https://doi.org/10.1136/bmj.h349.
-
Tita ATN, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy (CHAP Trial). N Engl J Med. 2022;386:1781–1792.
-
Gestational Hypertension and Preeclampsia (2020). Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstetrics Gynecol. 135 (6), e237–e260. https://doi.org/10.1097/AOG.0000000000003891
-
https://doi.org/10.1056/NEJMoa2201295 De Backer J., Haugaa K., et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. European Heart Journal. 2025;00:1-107. https://doi.org/10.1093/eurheartj/ehaf193.
-
Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT trial): a multicentre, open-label randomised controlled trial. Lancet. 2009;374(9694):979-988. https://doi.org/10.1016/S0140-6736(09)60736-4.
-
Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): a multicentre, ISSN: 3060-4850; CARDIOLOGY OF UZBEKISTAN 2026; 3 (1). 25 of 25 open-label randomised controlled trial. Lancet. 2015;385(9986):2492-2501. https://doi.org/10.1016/S0140-6736(14)61998-X.
-
Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews. 2018, Issue 10. Art. No.: CD002252. https://doi.org/10.1002/14651858.CD002252.pub4.
-
Sridharan K., Sequeira R.P. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906-1916. https://doi.org/10.1111/bcp.13649.PMID:29974489.
-
George R., Thomas C., Anna Joy C., Varghese B., Undela K., Adela R. Comparative efficacy and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2022;40(10):1876–1886. https://doi.org/10.1097/HJH.0000000000003233.
-
Yin J., Mei Z., Shi S., Du P., Qin S. Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. Arch Gynecol Obstet. 2022; 306(6): 1891–1900. https://doi.org/10.1007/s00404-022-06504-5.
-
Bajpai D., Popa C., Verma P., Dumanski S., Shah S. Evaluation and Management of Hypertensive Disorders of Pregnancy. Kidney360. 2023;4(10):1512-1525. https://doi.org/10.34067/KID.0000000000000228
About the Authors
License
Copyright (c) 2026 Мохинур Садуллоева, Феруза А. Закирова (Автор)
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
